Artigos com autorizações de acesso público - Dinko RekićSaiba mais
Disponíveis em algum local: 5
Clinical drug–drug interaction evaluations to inform drug use and enable drug access
D Rekić, KS Reynolds, P Zhao, L Zhang, K Yoshida, M Sachar, MP Miller, ...
Journal of pharmaceutical sciences 106 (9), 2214-2218, 2017
Autorizações: US Department of Energy
In vitro–in vivo extrapolation of metabolism-and transporter-mediated drug–drug interactions—overview of basic prediction methods
K Yoshida, P Zhao, L Zhang, DR Abernethy, D Rekić, KS Reynolds, ...
Journal of pharmaceutical sciences 106 (9), 2209-2213, 2017
Autorizações: US Department of Energy
Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy
D Rekić, O Clewe, D Röshammar, L Flamholc, A Sönnerborg, ...
The AAPS journal 13 (4), 598-605, 2011
Autorizações: Swedish Research Council
Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data
Y Aoki, CS Cabrera, M Ouwens, K Bamberg, J Nyström, I Raz, BM Scirica, ...
Plos one 17 (6), e0269970, 2022
Autorizações: National Institute for Health Research, UK
Adavosertib (AZD1775) does not prolong QT interval in patients with advanced solid tumors: A Phase I open-label study
M Någård, ML Ah-See, K So, J Strauss, T Wise-Draper, H Safran, D Wang, ...
Cancer Research 80 (16_Supplement), 591-591, 2020
Autorizações: US National Institutes of Health
As informações de publicação e financiamento são determinadas automaticamente por um programa informático.